Sign In
Buy VRCA
$5.87
+0.0800 (+1.38%)
At Close: Jun 03, 2026
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
08:05am, Thursday, 28'th May 2026
WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
08:00am, Wednesday, 13'th May 2026
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of
Verrica Pharmaceuticals Q1 Earnings Call Highlights
11:08pm, Tuesday, 12'th May 2026
Verrica Pharmaceuticals NASDAQ: VRCA reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development programs
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
09:40pm, Tuesday, 12'th May 2026
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
06:16pm, Tuesday, 12'th May 2026
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $1 per share a year ago.
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
04:01pm, Tuesday, 12'th May 2026
– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispen
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Ver
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
08:00am, Tuesday, 05'th May 2026
WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications
WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment o
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
08:00am, Monday, 06'th Apr 2026
WEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment o
Critical Survey: Verrica Pharmaceuticals (NASDAQ:VRCA) vs. Vivani Medical (NASDAQ:VANI)
01:03am, Sunday, 05'th Apr 2026
Vivani Medical (NASDAQ: VANI - Get Free Report) and Verrica Pharmaceuticals (NASDAQ: VRCA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast th
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
07:42pm, Friday, 20'th Mar 2026
LOS ANGELES--(BUSINESS WIRE)---- $VRCA--VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Verrica Pharmaceutic
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Verrica Pharmaceutic
Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call Transcript
11:22am, Wednesday, 11'th Mar 2026
Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call Transcript
